CClinicalTrials.gg
Sign In
CompletedNCT01875575Updated Jun 12, 2013

Oral Glucose Stimulation in Normal-weight and Obese Volunteers

An interventional study of Placebo and Glucose 25g in Endocrine System Diseases, sponsored by University Hospital, Basel, Switzerland. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-06-12.

Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The objective of this study is to examine gastric emptying and satiety hormones after oral glucose stimulation in 2 different concentrations in normal-weight and obese patients.

02

Conditions studied

  • Endocrine System Diseases

Keywords

  • glucagon-like peptide-1
  • peptide tyrosine tyrosine
  • ghrelin
  • stomach
  • small intestine
  • gastric emptying
03

In context

Endocrine System Diseases

307 studies on the registry are indexed under Endocrine System Diseases; 52 are open to participants now.

This study's enrollment of 24 is below the median of 69 across 216 interventional studies indexed under Endocrine System Diseases.

Browse Endocrine System Diseases studies →

Lead sponsor

University Hospital, Basel, Switzerland is the lead sponsor of 968 studies on the registry; 191 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy normal weight subjects with a body-mass index of 19.0-24.5 or healthy obese subjects with a body-mass index of > 30
  • Normal eating habits
  • Age 18-40 years
  • Stable body weight for at least three months

Exclusion criteria

Exclusion Criteria:

  • Smoking
  • Substance abuse
  • Regular intake of medications (except for oral contraceptives)
  • Medical or psychiatric illness
  • Any abnormality detected during the screening procedure
  • history of gastrointestinal disorders
  • food allergies
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Glucose 10g

    10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)via nasogastric tube

    Dietary Supplement: Glucose 10g

  • Active comparator
    Glucose 25g

    25g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)via nasogastric tube

    Dietary Supplement: Glucose 25g

  • Placebo comparator
    Placebo

    intragastric tap water

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementPlacebo
  • Dietary supplementGlucose 25g
  • Dietary supplementGlucose 10g
06

What researchers measure

Primary outcomes

  1. Effect of different oral glucose loads on secretion of satiation hormones

    Plasma concentrations of glucose, insulin, glucagon, ghrelin, GLP-1, PYY and CCK are measured

    Time frame: 240min.

Secondary outcomes

  1. Effect of different oral glucose loads on gastric emptying

    measured by C13 breath test

    Time frame: 240min.

07

Study locations

1 site
  • University Hospital Basel
    Basel, CH-4031, Switzerland
08

References and documents

Publications

  • Meyer-Gerspach AC, Cajacob L, Riva D, Herzog R, Drewe J, Beglinger C, Wolnerhanssen BK. Mechanisms Regulating Insulin Response to Intragastric Glucose in Lean and Non-Diabetic Obese Subjects: A Randomized, Double-Blind, Parallel-Group Trial. PLoS One. 2016 Mar 4;11(3):e0150803. doi: 10.1371/journal.pone.0150803. eCollection 2016. PubMed 26942445 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 12, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01875575
Lead sponsor
University Hospital, Basel, Switzerland
Responsible party
Sponsor
First posted
Jun 12, 2013
Start date
Feb 2013
Primary completion
Apr 2013
Completion
Apr 2013
Last update
Jun 12, 2013

Study contacts

Christoph Beglinger, Prof
principal investigator · University Hospital, Basel, Switzerland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Endocrine System Diseases→

Other studies from this sponsor

University Hospital, Basel, Switzerland

Start the discussion